Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs Differ

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 996-1001

  Gracia, Matilde ^a   Martínez Marín, Carmina ^a   Huelves, Lorena ^a   Giménez, Maria J ^b   Aguilar, Lorenzo ^b   Carcas, Antonio ^c   Ponte, Carmen ^a   Soriano, Francisco ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b GLAXOSMITHKLINE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; IN VITRO STUDY; KINETICS; LOBAR PNEUMONIA; LUNG INJURY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

AMOXICILLIN; ANIMALS; FEMALE; LUNG; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; RATS; RATS, SPRAGUE-DAWLEY; STREPTOCOCCUS PNEUMONIAE;

EID: 14744275072     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.996-1001.2005     Document Type: Article

References (26)

1. Azoulay-Dupuis, E., P. Moine, J. P. Bedos, V. Rieux, and E. Vallee. 1996. Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Antimicrob. Agents Chemother. 40:941-946.
2. Bartlett, J. G., and L. M. Mundy. 1995. Community-acquired pneumonia. N. Engl. J. Med. 333:1618-1624.
3. Bartlett, J. G., R. F. Breiman, L. A. Mandell, T. M. File, Jr., et al. 1998. Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26:811-838.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
5. Darras-Joly, C., J. P. Bédos, C. Sauve, P. Moine, E. Vallée, C. Carbon, and E. Azoulay-Dupuis. 1996. Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob. Agents Chemother. 40:2147-2151.
6. den Hollander, J. G., J. D. Knudsen, J. W. Mouton, K. Fuursted, N. Frimodt-Moller, H. A. Verbrugh, and F. Espersen. 1998. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob. Agents Chemother. 42:377-382.
7. Fenoll, A., C. M. Bourgon, R. Muñoz, D. Vicioso, and J. Casal. 1991. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev. Infect. Dis. 13:56-60.
8. File, T. M., Jr., M. R. Jacobs, M. D. Poole, B. Wynne, et al. 2002. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxicillin/clavulanate. Int. J. Antimicrob. Agents 20:235-247.
9. Frimodt-Moller, N. 1988. Correlation of in vitro activity and pharmacokinetic parameters with effect in vivo for antibiotics. Observations from experimental pneumococcus infection in mice. Danish Med. Bull. 35:422-437.
10. Frimodt-Moller, N. 1993. The mouse peritonitis model: present and future use. J. Antimicrob. Chemother. 31(Suppl. D):55-60.
11. Garau, J., M. Twynholm, E. García-Mendez, B. Siquier, A. Rivero, and the 557 Clinical Study Group. 2003. Oral pharmacokinetically enhanced coamoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J. Antimicrob. Chemother. 52:826-836.
12. Kaye, C. M., A. Allen, S. Perry, M. McDonagh, M. Davy, K. Storm, N. Bird, and O. Dewit. 2001. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin. Ther. 23:578-584.
13. Klassen, M., and K. A. Nash. 1996. Measurement of antibiotics in human body fluids: techniques and significance, p. 230-295. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, Md.
14. Liu, H. H., and A. Tomasz. 1985. Penicillin tolerance in multiply drug-resistant natural isolates of Streptococcus pneumoniae. J. Infect. Dis. 152:365-372.
15. Lodise, T., P. S. McKinnon, L. Swiderski, and M. J. Rybak. 2003. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. 36:1418-1423.
16. National Center for Health Statistics. 1992. Advanced report of final mortality statistics, vol. 42. National Center for Health Statistics, Hyattsville, Md.
17. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Normark, B. H., and S. Normark. 2002. Antibiotic tolerance in pneumococci. Clin. Microbiol. Infect. 8:613-622.
19. Pallarés, R., J. Liñares, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martín, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe penumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
20. Parra, A., C. Ponte, C. Cenjor, C. Martínez-Marín, F. Soriano, and the Spanish Pneumococcal Infection Study Network. 2004. Effect of antibiotic treatment delay on therapeutic outcome of experimental acute otitis media caused by Streptococcus pneumoniae strains with different susceptibilities to amoxicillin. Antimicrob. Agents Chemother. 48:860-866.
21. Pérez-Trallero, E., C. Fernández-Mazarrasa, C. García-Rey, E. Bouza, L. Aguilar, J. García-de-Lomas, F. Baquero, and the Spanish Surveillance Group for Respiratory Pathogens. 2001. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob. Agents Chemother. 45:3334-3340.
22. Petitpretz, P., C. Chidiac, F. Soriano, J. Garau, K. Stevenson, E. Ruffiac, and the 556 Clinical Study Group. 2002. The efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate 2000/125 mg, twice daily, versus oral amoxicillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int. J. Antimicrob. Agents 20:119-129.
23. Ponte, C., A. Parra, E. Nieto, and F. Soriano. 1996. Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime and meropenem. Antimicrob. Agents Chemother. 40:2698-2702.
24. Rowland, M., and T. Tozer. 1995. Clinical pharmacokinetics: concepts and applications, 3rd ed. Williams & Wilkins, Baltimore, Md.
25. Sahm, D. F., J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, Y. Mauriz, and J. Kahn. 2001. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob. Agents Chemother. 45:1037-1042.
26. Woodnutt, G., and V. Berry. 1999. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:35-40.